All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

@elldicken's 3 stone weight loss on Wegovy, fact-checked

Ellie | mama to 2 under 2

TikTok creator

61.1K viewsWatch on TikTok→

Quick answer

Semaglutide (Wegovy) is a GLP-1 receptor agonist that reduces appetite and slows gastric emptying. The STEP 1 trial demonstrated 14.9% average weight loss over 68 weeks at the 2.4mg maintenance dose. Treatment requires ongoing use to maintain weight loss benefits.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.

What does this video actually claim?

@elldicken shares her weight loss transformation using Wegovy, claiming she's lost 3 stone (42 pounds) and gained confidence. The video shows before-and-after photos documenting her physical changes on the GLP-1 medication.

Her caption is refreshingly straightforward compared to many weight loss TikToks. She doesn't make wild promises about timeline or results everyone can expect. The focus stays on her personal experience rather than medical advice.

The hashtags suggest this is part of a broader "Wegovy journey" narrative that's become popular on social media platforms.

Is 3 stone of weight loss realistic on Wegovy?

Absolutely. The STEP 1 trial (Wilding et al., NEJM, 2021) found participants lost an average of 14.9% of their body weight over 68 weeks on 2.4mg semaglutide. For someone starting at 280 pounds, that's roughly 42 pounds.

The STEP 2 trial showed even higher losses in people with diabetes. At 68 weeks, participants on 2.4mg semaglutide lost 9.6% of body weight compared to 3.4% on placebo.

What @elldicken doesn't mention is timeline, which matters. Most people don't see maximum weight loss until month 16-20 of treatment. The medication works by slowing gastric emptying and reducing appetite through GLP-1 receptor activation in the brain.

What's missing from her story?

The video skips over Wegovy's side effects, which hit most users hard initially. The STEP 1 trial reported nausea in 44.2% of participants, vomiting in 24.8%, and diarrhea in 29.8%.

She also doesn't mention the cost reality. Wegovy runs about $1,200-1,400 monthly without insurance coverage. Many insurance plans still don't cover it for weight loss.

The confidence boost she mentions is real but incomplete. Weight regain typically happens if you stop the medication. The STEP 1 withdrawal study showed participants regained two-thirds of lost weight within a year of stopping treatment.

Should you trust transformation posts like this?

@elldicken's post is more honest than most weight loss content online. She doesn't promise quick fixes or claim everyone will get identical results. Her 3 stone loss falls within expected ranges from clinical trials.

But individual results vary wildly with GLP-1 medications. In STEP 1, 32% of participants lost at least 20% of their body weight, while others saw minimal changes despite staying on the full dose.

The real question isn't whether Wegovy works (it does), but whether you can access it consistently and afford long-term treatment. That's the part most transformation videos conveniently skip.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksCompounded SemaglutideProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Compounded Semaglutide access requires the right clinical path

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 6 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @elldicken's 3 stone weight loss on Wegovy, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Video claim decision path

Turn the claim into a safer next question

Direct answer

Compounded Semaglutide should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.

Evidence check

Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.

Safety check

A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.

Next step

Use the health tools and supporting evidence to prepare questions for your clinician.

Claim path

Keep researching this semaglutide video claims cluster

Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.

Claim verdict

The useful answer behind this video

Claim being checked

Semaglutide (Wegovy) is a GLP-1 receptor agonist that reduces appetite and slows gastric emptying.

FormBlends verdict

Semaglutide (Wegovy) is a GLP-1 receptor agonist that reduces appetite and slows gastric emptying. The STEP 1 trial demonstrated 14.9% average weight loss over 68 weeks at the 2.4mg maintenance dose. Treatment requires ongoing use to maintain weight loss benefits.

Patient-safe next step

Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • Semaglutide (Wegovy) is a GLP-1 receptor agonist that reduces appetite and slows gastric emptying. The STEP 1 trial demonstrated 14.9% average weight loss over 68 weeks at the 2.4mg maintenance dose. Treatment requires ongoing use to maintain weight loss benefits.
  • The STEP 1 trial found 14.9% average weight loss with 2.4mg semaglutide over 68 weeks
  • 3 stone (42 pounds) weight loss falls within expected ranges for Wegovy users

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.

Review Compounded Semaglutide

What You'll Learn

  • The STEP 1 trial found 14.9% average weight loss with 2.4mg semaglutide over 68 weeks
  • 3 stone (42 pounds) weight loss falls within expected ranges for Wegovy users
  • 44.2% of STEP 1 participants experienced nausea as a common side effect
  • Wegovy costs $1,200-1,400 monthly without insurance coverage
  • Weight regain typically occurs if treatment stops, with two-thirds of weight returning within a year
  • 32% of trial participants lost at least 20% of their body weight on maximum doses
  • Individual results vary significantly despite consistent dosing and adherence

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Ellie | mama to 2 under 2 · TikTok creator

61.1K views on this video

3 stone down, confidence up 💃✨ #fyy #wegovyjourney #weightlosstransformation #weightlossglowup #f

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Ellie | mama to 2 under 2, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.